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Abstract:  Sleep loss is a common condition in developed countries, with evidence showing that people in Western 
countries are sleeping on average only 6.8 hour (hr) per night, 1.5 hr less than a century ago. Although the effects of sleep 
deprivation on our organs have been obscure, recent epidemiological studies have revealed relationships between sleep 
deprivation and hypertension (HT), coronary heart disease (CHD), and diabetes mellitus (DM). This review article 
summarizes the literature on these relationships. Because sleep deprivation increases sympathetic nervous system activity, 
this increased activity serves as a common pathophysiology for HT and DM. Adequate sleep duration may be important 
for preventing cardiovascular diseases in modern society. 
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INTRODUCTION 
  In the 1980s, at the peak of the Japanese economic boom, 
work exhaustion and sleep deprivation were blamed for large 
number of deaths. Most cases of “karoshi”, or “death from 
overwork”, involved acute cardiovascular events [1]. 
Likewise in the United States, a recent National Sleep 
Foundation poll [2], found that many Americans have long-
term sleep deprivation. Only about one-third of the 
population (37%) reported getting 8 hour (hr) of sleep per 
night, and 31% reported 6 hr or less [3]. Sleep loss is a 
common condition in modern society, with evidence 
showing that people are sleeping on average only 6.8 hr per 
night, 1.5 hr less than a century ago [4, 5]. 
   Although the effects of sleep deprivation on the organs 
have been obscure, recent studies revealed relationships 
between sleep deprivation and hypertension (HT), coronary 
heart disease (CHD), and diabetes mellitus (DM). This 
article reviews the literature on these relationships.  
  Pickering have reviewed mainly the relationship between 
sleep duration and hypertension elsewhere, and observed an 
independent association of sleep duration to incidence of 
hypertension. This review will focus on the role of sleep 
duration, in particular short sleep duration, as a risk factor 
for development of hypertension, coronary heart disease, and 
diabetus mellitus. To set the stage, we summarized current 
insights in the epidemiology for these relationships, and 
updated the possible pathophysiology in the association of 
sleep duration with HT, CHD, and DM [6]. 
  From the standpoint of sleep quality, sleep apnea 
syndrome should be taken into account. However, some 
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excellent review articles have already summarized the effects 
of sleep apnea syndrome on HT [7], CHD [8], and DM [9]. 
SLEEP DURATION AND MORTALITY 
  In the Alameda County Study, Wingard and Berkman 
[10] investigated the mortality risk associated with different 
sleeping patterns based on date from a 9-year mortality 
follow-up of 6928 adults. The analysis indicated that 
mortality rates from ischemic heart disease, cancer, stroke, 
and all causes combined were lowest for individuals sleeping 
7 or 8 hr per night. Men sleeping 6 hr or less, or 9 hr or 
more, had 1.7 times the total age-adjusted death rate of men 
sleeping 7 or 8 hr per night. The comparable relative risk for 
women was 1.6. In prospective epidemiologic data from the 
American Cancer Society [11], men who reported that they 
usually sleep less than 4 hr were 2.80 times as likely to have 
died within 6 years as men who reported 7.0 to 7.9 hr of 
sleep. The ratio for women was 1.48. Men and women who 
reported sleeping 10 hr or more had about 1.8 times the 
mortality of those who reported 7.0 to 7.9 hr of sleep. The 
relationship between sleep duration and mortality was U-
shaped. 
EFFECTS OF SLEEP DURATION ON HT, CHD, AND 
DM (TABLE 1) 
Sleep Duration and HT 
  The prevalence of HT has increased over the past decade 
despite improvements in awareness, treatment, and control 
of this disease [12]. During the same period, the average 
sleep duration in the United States has steadily declined [13]. 
  In the First National Health and Nutrition Examination 
Survey (NHANES), Gangwisch et al. [14] conducted 
longitudinal analyses for 8 to 10 years on 4810 subjects from 
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duration increased HT incidence. Of these, 647 subjects were 
diagnosed with HT in that period. Sleep duration of < 5 hr 
per night was associated with a significantly increased risk 
of HT in subjects between the ages of 32 and 59 years. 
However, this significant relationship was not found in 
subjects between aged of 60 to 86 years.  
  This result would suggest a strong association between 
short sleep duration and the development of HT, especially 
in middle-aged subjects. 
Mechanism Underlying the Relationship between Sleep 
Duration and HT  
  Short sleep duration was associated with the development 
of HT. This may be attributable in part to autonomic dys-
regulation that changes the predominant neutral interaction 
of sympathovagal balance during sleep into increased 
sympathetic tone. In 24 hr ambulatory blood pressure 
monitoring (ABPM) studies, BP tended to rise the day after 
sleep deprivation in both normotensives [15] and hyper-
tensives [16].
 Similarly, Tochikubo [17] et al. showed signi-
ficant increases in BP, low-frequency/high-frequency 
(LF/HF) ratio, and urinary excretion of norepinephrine, 
especially in the evening, the day after sleep deprivation in 
18 male technical workers aged 23 to 48 years (Fig. 1). 
These data suggest that a lack of sleep may increase 
sympathetic nervous system activity the next day. Zhong et 
al. [18]
  assessed cardiovascular autonomic modulation 
during 36 hr of total sleep deprivation in 18 normal healthy 
subjects. LF was significantly increased at 12 and 24 hr, as 
was LF/HF at 12 hr, whereas HF was decreased at 12 hr of 
sleep deprivation.  
    Using polysomnography, Irwin et al. [19]
  examined 
whether or not nocturnal vagal tone indexed by HF was 
related to measures of sleep depth and daytime perceptions 
of sleep quality, sleepiness, and fatigue in alcohol-dependent 
patients. Compared with the controls, these patients showed 
decreses in delta sleep time along with impairments in sleep 
quality, daytime energy, and the HF component both before 
and during sleep.  
  Irwin and Ziegler [20] investigated whether or not sleep 
deprivation induces differential cardiovascular and 
sympathetic responses, and measured heart rate, BP, and 
circulating sympathetic catecholamines in 36 abstinent 
alcohol-dependent men and 36 age-, gender-, and ethnicity-
matched controls. Although baseline heart rate, BP, and 
sympathetic catecholamines were similar in both groups, 
partial night sleep deprivation induced greater increases in 
heart rate and circulating levels of norepinephrine and 
epinephrine in the alcohol-dependent men than in controls. 
  Vascular lesions with atherosclerosis are filled with 
immune cells that effect inflammatory responses. These 
responses are suggested to initiate plaque activation that 
progress hypertensive status. Born et al. have shown that 
stimulated ex vivo production of interleukin-2 (IL-2) is 
higher during sleep suggesting that this effect is dependent 
Table 1.  The Relationship between Sleep Duration and the Risk of Hypertension, Coronary Heart Disease, and Diabetes Mellitus 
  Study or 
Author  
Subject  Age 
(Year) 
Follow-up 
period 
Result 
Hypertension (HT)   NHANES 
(2006)
4810 subjects 
without HT
 2574 8 - 10 (years)  •  Increased risk of HT in subjects with 5 or 
fewer hours of sleep.
Coronary heart 
disease (CHD) 
Nurses’ Health 
Study (2003)
71,617 females 
without CHD 
 4565  10 (years)  •  Increased risk of CHD in subjects with 5 or 
fewer, 6, 7, and 9 or more compared with 
those with 8 hours of sleep.  
•  U-shaped phenomenon (+).
 Liu  et al. (2006) 260 males with 
AMI and 422 
males without 
AMI 
4079 (-) (case- control 
study
•  Increased odds ratios of AMI in subjects with 
5 or fewer compared with those with 6 to 8 
hours of sleep.
Diabetes mellitus 
(DM) /Impaired 
glucose  tolerance  
(IGT) 
SHHS (2005) 722 males and 
764 females 
5393 (-) (cross- 
sectional  
design
•  Increased odds ratios of DM and IGT in 
subjects with 5 or fewer, 6, and 9 or more 
compared with those getting 7 to 8 hours of 
sleep.  
•  U-shaped phenomenon (+). 
   MMAS (2006) 1709 males 
without DM 
4070 15  (years)  •  Increased risk of DM in subjects with 5 or 
fewer, 6, and 8 or more compared with those 
getting 7 hours of sleep.  
•  U-shaped phenomenon (+). 56    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Kario et al. 
on sleep [21, 22].
 Conversely, partial night sleep deprivation 
induced decreases in stimulated production of IL-2 and 
natural killer cell responses [23, 24].  
 Irwin  et al. [25] measured circulating levels of 
catecholamines and IL-2 sampled every 30 minutes during 
two nights: undisturbed, baseline sleep and partial sleep 
deprivation-late night (PSD-L; awake from 0300-0600) in 17 
healthy male volunteers. On the PSD-L night, levels of 
norepinephrine and epinephrine significantly increased in 
association with nocturnal awakening. Nocturnal levels of 
circulating IL-2 did not change with sleep onset or in relation 
to PSD-L or various sleep stages.  
  Elevated plasma concentrations of C-reactive protein 
(CRP) are indicative of systemic inflammation. Circulating 
CRP levels are representative marker of vascular damage 
progression. In this point, higher CRP level would be 
associated with incidence of HT. Meier-Ewert et al. [26] 
measured high-sensitivity C-reactive protein (hs-CRP) 
collected every 90 minutes for 5 consecutive days in 10 
healthy adults who stayed awake for 88 continuous hours. 
The hs-CRP concentrations and systolic BP increased during 
that period. 
  Additionally, excessive waking periods would induce 
long-standing psycho-social stress. Recently, stress exposure 
has been found to lead to increased salt intake and inhibition 
of renal salt excretion [27]. These processes may be related 
to HT development during volume overload for 24 hr and to 
arterial remodeling. 
  In short, sleep deprivation is associated with increased 
sympathetic tone. Sleep loss might serve to elevate nocturnal 
catecholamine levels and contribute to cardiovascular 
disease.  
Sleep Duration and CHD 
  Short sleep duration imposed on a group of healthy 
subjects increased sympathetic nervous system activity and 
blood pressure elevation. Therefore sustained short sleep 
duration could lead to adverse cardiovascular consequence.  
  A prospective study in the United States showed that the 
standardized mortality ratio of CHD was highest among 
those who worked 67 hr or more a week [28].
 Case-control 
studies in The Netherland [29], Denmark [30], and Sweden 
[31] also reported that prolonged working time was asso-
ciated with an increased risk of acute myocardial infarction 
(AMI). Another case-control study in Japan found signifi-
cantly increased odds ratios of AMI for those who worked 
more than 11 hr a day [32]. 
   It is possible to think that sleep deprivation caused by 
overtime work is associated with an increased risk of AMI. 
The American Cancer Society Study showed that men 
sleeping 4 hr or less had higher mortality from CHD than 
those sleeping 7-7.9 hr [11]. The Alameda County Study 
[10] and the study by Partinen et al. [33] also noted that men 
who slept less than 6 hr had a greater risk of developing 
CHD than men sleeping 7-8 hr. 
   In a Japanese case-control study, Liu et al. [34] examined 
the relationships between the risk of AMI and both work 
hours and sleep duration. The cases were 260 men aged 40-
79 admitted to hospitals with AMI during 1996-8. The 
controls were 445 AMI-free men matched for age and 
residence who were recruited from the resident registers. 
Longer working hours were related to shorter hours of sleep, 
and more days a week with less than 5 hr in both AMI 
patients and normal healthy subjects. Working more than 60 
hours per week was related to increased incidence of AMI; 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Means of ambulatory blood pressure on a normal workday and a sleep-insufficient day. BP indicates blood pressure; SBP1, systolic 
BP on sleep-insufficient day; SBP2, systolic BP on normal workday; DBP1, diastolic BP on sleep-insufficient day; DBP2, diastolic BP on 
normal workday. (From Tochikubo et al. [16]. Hypertension 1996; 27: 1318-1324).  Cardiovascular Disease- a Review of the Recent Literature  Current Cardiology Reviews, 2010, Vol. 6, No. 1    57 
those working such hours were twice as likely to develop 
AMI than those working no more than 40 hours. Those who 
slept no more than 5 hr per night had a 2.3-fold greater risk 
of AMI than those getting 6-8 hr sleep. 
   In the Nurses’ Health Study, Ayas et al. [35]
 investigated 
the relationship between self-reported sleep duration and the 
incidence of CHD in 71,617 female health professionals 
aged 45-65 years in the United States. A total of 934 
coronary events were documented (271 fatal and 663 
nonfatal) during the 10 years of follow up. The age-adjusted 
relative risks of CHD, with 8 hr of daily sleep being 
considered the reference group, for individuals reporting 5 or 
fewer, 6, and 7 hr of sleep were 1.82, 1.30, and 1.06, 
respectively. The relative risk for 9 or more hr of sleep was 
1.57. 
  These reports support the notion that short or long sleep 
duration is independently associated with an increased 
likelihood of coronary events. There is thus a U-shaped 
relationship between sleep duration and CHD incidence. 
  Several biological explanations are possible for the 
increased risk of CHD associated with sleep deprivation. 
Hypertension and increased sympathetic nervous system 
activity may underlie this relationship. Sleep deprivation also 
increases sympathetic nervous system activity, heart rate, 
and vasoconstriction as well as salt retention. These factors 
may be associated with hypertension caused by cardiac 
overdrive and volume overload. 
  On the other hand, there have been few reports on the 
relationship between long sleep duration and CHD. Sleep 
apnea syndrome would be a candidate factor for this 
relationship, but there is little evidence as to whether patients 
with sleep apnea have long sleep duration or not. 
Sleep Duration and DM 
 Spiegel  et al. [36] assessed the activity of the hypo-
thalamo-pituitary-adrenal axis and sympathovagal balance in 
11 young men under two different sets of conditions: after 
their time in bed had been restricted to 4 hr per night for 6 
consecutive nights, and after a sleep-recovery period when 
the participants were allowed 12 hr in bed per night for 6 
consecutive nights. Lower glucose tolerance, higher evening 
cortisol concentration, and increased activity of the sym-
pathetic nervous system occurred in the sleep deprivation 
experiment than in the fully rested condition. Similar results, 
that sleep deprivation was associated with lower glucose 
tolerance and increased insulin resistance, were found 
elsewhere [37]. 
  Whereas these results were based mainly on an 
experimental sleep restriction, the metabolic effects of 
habitual sleep restriction were reported recently. In the Sleep 
Heart Health Study (SHHS) [38], 722 men and 764 women, 
aged 53 to 93 years, were assessed to determine the cross-
sectional relationship between usual sleep time and both DM 
and impaired glucose tolerance (IGT). Compared with those 
sleeping 7 to 8 hr per night, subjects sleeping 5 hr or less and 
6 hr per night had adjusted odds ratios of 2.51 and 1.66 for 
DM and of 1.33 and 1.58 for IGT, respectively. Subjects 
sleeping 9 hr or more per night also had increased odds 
ratios for DM and IGT. These associations persisted when 
subjects with insomnia were excluded. 
  In the Massachusetts Male Aging Study (MMAS) [39], a 
cohort of men
 without DM at baseline were followed for the 
development of DM for 15 years. When those reporting 7 hr 
of sleep per night served as the reference group, men 
reporting less sleep (<5 and 6 hours sleep per night) were 
twice as likely to develop DM, and men reporting long sleep 
duration (>8 hours of sleep per night) were more than three 
times as likely to develop DM during the follow-up period. 
The risk elevation remained essentially unchanged after 
adjustments for age, hypertension, smoking status, self-rated 
health status, education, and waist circumference.  
  Short or long sleep duration increases the risks of 
developing DM, independent of confounding factors. This 
suggests that U-shaped associations exist between sleep 
duration and the incidence of DM. 
  Short sleep duration was associated with disruption of 
endogenous system via increased sympathetic nervous 
system activity. Several studies have identified some agents 
that links short sleep duration and incidence of DM. 
  Experimental sleep deprivation causes elevated evening 
levels of cortisol that may predispose individuals to insulin 
resistance [36, 40]. On the other hand, recent studies have 
linked sleep disruption with reduced testosterone levels [41]. 
Low levels of testosterone have been associated with obesity 
[42], elevated levels of insulin and glucose [43, 44], and DM 
incidence [45, 46]. In the MMAS [39], not cortisol but 
testosterone level had considerable impact on the rela-
tionship between sleep duration and DM incidence among 
male subjects. In addition to this, sleep deprivation reduced 
levels of leptin and increased levels of ghrelin. Increased 
appetite was correlated with an increased ratio of ghrelin to 
leptin [47]. 
  Sleep restriction results in an increase in sympathetic 
tone, which inhibits pancreatic function [36, 48]. Autonomic 
nervous system dysregulation may be also associated with 
the impact of sleep deprivation on the increased incidence of 
DM. 
  On the other hand, few studies have investigated the 
effect of long-term sleep duration on triggering DM. Sleep-
disordered breathing, a known cause of daytime sleepiness, 
would be linked to increased sympathetic tone and glucose 
intolerance [7]. These mechanisms may be associated with 
the relationship between long sleep duration and DM. 
  In summary, sleep loss was associated with DM via 
endocrine system disruption, which would, in part, affect our 
eating behavior and autonomic balance 
SLEEP DEPRIVATION AND DECREASED 
MELATONIN SECRETION  A POSSIBLE LINK 
WITH THE NCREASED SYMPATHETIC NERVOUS 
SYSTEM ACTIVITY DURING SLEEP (FIG. 2). 
  Recent studies have shown that dysregulation of 
melatonin secretion may be associated with HT and IGT. 
The suprachiasmatic nucleus (SCN) in the hypothalamus, 
which serves as an essential component of the circadian 
clock, affects melatonin secretion. Light activates SCN 58    Current Cardiology Reviews, 2010, Vol. 6, No. 1  Kario et al. 
neurons via retino-hypothalamic glutamate secretion. The 
SCN reaches autonomic neurons of the paraventricular 
nucleus (PVN) which projects to the intermediolateral 
column of the spinal cord (IML) where preganglionic 
sympathetic neurons are located that control the outflow to 
the pineal gland [49-51]. The activation of SCN neurons has 
been suggested to cause a release of a specific -
aminobutyric acid (GABA) from their terminals in the PVN 
and consequently may inhibit melatonin secretion [52-54]. 
  Injection of transneuronal tracers into various organs 
ranging from heart to ovaries and from white to brown 
adipose tissue resulted in the labeling of neurons in the SCN 
via the sympathetic and parasympathetic branches of the 
autonomic nervous system [55-58]. These data demonstrate 
that the SCN may transmit its circadian message, influencing 
the activityrest cycle of peripheral organs, not only by the 
secretion of hormones that may freely pass all kinds of tissue 
barriers, such as melatonin, corticosterone, gonadal hor-
mones and thyroid hormones but also by direct nervous 
system control of these organs. And, SCN neurons are 
labeled via both the sympathetic and parasympathetic 
systems, indicating that the SCN may indeed support both 
the activity and rest periods of the circadian cycle.
  The SCN-PVN-autonomic axis affects hormone secretion 
and the sensitivity of the target organs to these hormones 
through neuronal mechanisms. For example, anatomical and 
physiological evidence shows that the SCN influences the 
level of insulin secretion from the pancreas [59-61]. 
Additionally, when the SCN stimulates glucose secretion 
from the liver, at the same time it stimulates glucose uptake 
by other tissues [61].
 
  This timely orchestrated action of the SCN on glucose 
metabolism prepares the body, just before waking, for the 
coming period of activity. Disruption of this orchestration 
may be associated with the pathophysiology of HT and DM. 
  For a long time, physiological studies have indicated that 
patients suffering from these diseases exhibit disturbed 
circadian rhythm [62, 63].
Severe decreases in staining for 
several SCN neurotransmitters in hypertensive patients 
revealed an anatomical basis for these disturbances [64]. 
Interestingly, the finding that followed this observation was 
that, in the same patients, the activity of PVN corticotropin-
releasing hormone (CRH) neurons in the PVN was 
enhanced, which would suggest that the SCN would have an 
inhibitory effect on the PVN CRH neurons. This intriguing 
observation suggests that SCN activity is changed by a 
different autonomic feedback in HT. Since the SCN anatomy 
was changed in spontaneous hypertensive rats (SHR), and 
since transplantation of the hypothalamus containing the 
SCN from SHR to normotensive rats induced HT, it follows 
that a changed SCN might precede the development of HT 
[64].
Furthermore, recent evidence supports the notion that 
circadian disturbances can be detected before the 
development of HT or DM [65, 66]. 
HOW LONG SHOULD WE SLEEP? WHAT SLEEP 
MEDICATION SHOULD WE CHOOSE? 
  In brief, recent studies suggest that sleep deprivation is a 
significant risk factor for developing HT, CHD, or DM. In 
the evening of the day after sleep deprivation, sympathetic 
nervous system activity and BP are elevated. These increases 
may be associated with the increased risk of CHD. On the 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Chart for the relationships between sleep deprivation and hypertension, diabetes mellitus, and coronary heart disease. Cardiovascular Disease- a Review of the Recent Literature  Current Cardiology Reviews, 2010, Vol. 6, No. 1    59 
other hand, because sleep deprivation is related to reduced 
salt excretion or IGT, excessive intake of calories or salt 
should be avoided by people who are not getting enough 
sleep. In addition, since alcohol intake with sleep deprivation 
tends to elevate BP the next evening, people also should 
avoid drinking alcohol after not getting enough sleep. 
  Short sleep time is associated with increased sympathetic 
nervous system activity, which may point to this hypothesis 
that  or  adrenergic sympathetic blockade may be suitable 
for hypertensives who have sleep deprivation or IGT, 
because these sympathetic blockades have been shown to 
preserve pancreas function [67]. However, there is little 
evidence to support the notion that a sympathetic system 
blockade could be truly beneficial to such populations. 
 Recently,  Scheer  et al. [68] conducted a randomized, 
double-blind, placebo-controlled crossover trial in 16 men 
with untreated essential HT to investigate the influence of 
acute (single) and repeated (daily for 3 weeks) oral 
melatonin (2.5 mg) intake 1 hr before sleep on 24 hr ABP 
and sleep quality. Repeated melatonin intake reduced 
nocturnal systolic and diastolic BP by 6 and 4 mmHg, 
respectively (Fig. 3). The treatment did not affect heart rate. 
Repeated but not acute melatonin intake also improved 
sleep. These findings suggested that support of the circadian 
pacemaker function may provide a new strategy for the 
treatment of essential hypertension. 
 Similarly,  Cagnacci  et al. [69] investigated whether or 
not prolonged nocturnal administration of melatonin could 
influence daily BP rhythm in women. In a randomized, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Means of ambulatory blood pressure after repeated 
melatonin and repeated placebo sadministration. The light-gray 
background indicates the average period in bed. (From Scheer et al. 
(66). Hypertension 2004; 43: 192-197) 
double-blind, placebo-controlled crossover study, 9 females 
Table2.  The Relationship between Melatonin Administration and BP Control 
Author (Year)  Subjects (Age)  Melatonin  Study design  Treat period  Results 
Scheer et al. 
(2004) 
18 men with 
untreated HT 
(55±8 mean age)
Oral melatonin 
(2.5mg) intake 
1hr before sleep
Randomized,  
Double blind, 
placebo controlled, 
crossover 
3 week  •  Melatonin intake reduced systolic and 
diastolic blood pressure during sleep by 
6 and 4mmHg. 
•  Day-night amplitudes of the rhythms in 
systolic and diastolic blood pressures 
were increased by 15% and 25%. 
Cagnacci et al. 
(2005) 
9 normotensive 
women and 9 
women with 
treated HT (47 to 
63 years of age)
Oral melatonin 
(3.0mg) intake 
1hr before sleep
Randomized, 
double blind, 
placebo controlled, 
crossover 
3 week  •  Melatonin intake reduced systolic and 
diastolic blood pressure during sleep by 
3.8 and 3.6mmHg. 
•  Melatonin intake was related to the 
increase in the day-night BP difference.
Grossman et al. 
(2006) 
38 treated HTs 
with nocturnal HT 
(22 males, 64±11 
mean age)
Oral melatonin 
(2.0mg) intake 
2hr before sleep 
Randomized, 
double blind, 
placebo controlled
4 week •  Melatonin intake reduced nocturnal 
systolic BP from 136±9 to 
130±10mmHg, and diastolic BP from 
72±11 to 69±9mmHg. 
•  The reduction in nocturnal systolic BP 
was significantly greater with melatonin 
than with placebo.
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with normal BP and 9 females who were treated essential 
hypertensives received a 3-week course of melatonin (3 mg) 
or placebo intake 1 hr before going to bed. ABP was 
measured to evaluate BP reduction with melatonin intake. In 
comparison with placebo, melatonin administration did not 
influence diurnal BP but did significantly decrease nocturnal 
systolic and diastolic BP, by 3.7 and 3.6 mmHg, respec-
tively. 
 Additionally,  Grossman  et al. [70]
 studied the potency of 
melatonin to reduce nighttime BP. The 38 treated hyper-
tensive patients (16 females) with nocturnal hypertension 
were randomized in a double-blind fashion to receive either 
controlled-release melatonin (2 mg) or placebo 2 hrs before 
bedtime for 4 weeks. Melatonin treatment reduced nocturnal 
systolic and diastolic BP significantly, whereas placebo had 
no effect on nocturnal BP (Table 2). 
  Simko and Paulis [71] summarized a potential role of 
melatonin in antihypertensive treatment. The nighttime 
production of melatonin is found to be reduced in hyper-
tensive individuals. Melatonin administration decreased BP 
in several animal models of hypertension, in healthy men 
and women, and in patients with arterial HT. The most 
promising results were achieved in patients with nondipping 
nocturnal BP. Simko and Paulis [71] considered several 
potential mechanisms of BP reduction in melatonin, as 
follows. Melatonin can, via its scavenging and antioxidant 
nature, improve endothelial function via the increased 
availability of nitric oxide, thereby exerting vasodilatory and 
hypotensive effects, it can also interfere with the peripheral 
and central autonomic nervous systems, with a subsequent 
decrease in the tone of the adrenergic system and an increase 
in the cholinergic system.
CONCLUSION 
  The recent literatures confirms that sleep deprivation is 
associated with HT, CHD, and DM. Increased sympathetic 
nervous system activity is considered to serve as a common 
pathophysiology in sleep deprivation’s relationships with 
these diseases. Especially, the relationship between sleep 
time and incidence of CHD or DM is U-shaped. Sleep 
periods that are neither too short nor too long may be 
important to keep us healthy.  
REFERENCES 
[1]  Uehata T. Long working hours and occupational stress-related 
cardiovascular attacks among middle-aged workers in Japan. J 
Hum Ergol 1991; 20: 147-53. 
[2]  National Sleep Foundation.  National Sleep Foundation Sleep 
Survey. Washington, DC: National Sleep Foundation; 2001. 
[3]  Bonnet MH, Arand DL. We are chronically sleep deprived. Sleep 
1995; 18: 908-11. 
[4]  Webb WB, Agnew HW. Are we chronically sleep deprived? Bull 
Psychon Soc 1975; 6: 47-8. 
[5]  National Sleep Foundation: Sleep in America Poll 2003. 
Washington, DC, National Sleep Foundation, 2003. 
[6]  Pickering TG. Could hypertension be a consequence of the 24/7 
Society? The effects of sleep deprivation and shift work. J Clin 
Hypertens (Greenwich) 2006; 819-22. 
[7]  Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, 
and hypertension. Hypertension 2003; 42: 1067-74. 
[8]  Leung RS, Bradley TD. Sleep apnea and cardiovascular disease. 
Am J Respir Crit Care Med 2001; 164: 2147-65. 
[9]  Punjabi NM, Polotsky VY. Disorders of glucose metabolism in 
sleep apnea. J Appl Physiol 2005; 99: 1998-2007. 
[10]  Wingard DL, Berkman LF. Mortality risk associated sleeping 
patterns among adults. Sleep 1983; 6: 102-7. 
[11]  Kripke DF, Simons RN, Garfinkel L, Hammond EC. Short and 
long sleep and sleeping pills. Arch Gen Psychiatry 1979; 36: 103-
16. 
[12]  Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, 
and control of hypertension in the United States, 1988-2000. 
JAMA 2003; 290: 199-206. 
[13]  National Sleep Foundation. 2002 “Sleep in America” Poll. 
Washington, DC: National Sleep Foundation; 2002. 
[14]  Gangwisch JE, Heymsfield SB, Boden-Albala B, et al. Short sleep 
duration as a risk factor for hypertension. Analyses of the First 
National Health and Nutrition Examination Survey. Hypertension 
2006; 47: 833-9. 
[15]  Lusardi P, Mugellini A, Preti P, Zoppi A, Derosa G, Fogani R. 
Effects of a restricted sleep regimen on ambulatory blood pressure 
monitoring in normotensive subjects. Am J Hypertens 1996; 9: 
503-5. 
[16]  Lusardi P, Zoppi A, Preti P, Pesce RM, Piazza E, Fogari R. Effects 
of insufficient sleep on ambulatory blood pressure in hypertensive 
patients: A 24-h study. Am J Hypertens 1999; 12: 63-8. 
[17]  Tochikubo O, Ikeda A, Miyajima E, Ishii M. Effect of insufficient 
sleep on blood pressure monitored by a new multibiomedical 
recorder. Hypertension 1996; 27: 1318-24. 
[18]  Zhong X, Hilton HJ, Gates GJ, et al. Increased sympathetic and 
decreased parasympathetic cardiovascular modulation in normal 
humans with acute sleep deprivation. J Appl Physiol 2005; 98: 
2024-2032. 
[19]  Irwin MR, Valladares EM, Motivala S, Thayer JF, Ehlers CL. 
Association between nocturnal vagal tone and sleep depth, sleep 
quality, and fatigue in alcohol dependence. Psychosom Med 2006; 
68: 159-66. 
[20]  Irwin MR, Ziegler M. Sleep deprivation potentiates activation of 
cardiovascular and catecholamine responses in abstinent alcoholics. 
Hypertension 2005; 45: 252-7. 
[21]  Born J, Lange T, Hansen K, Molle M, Fehm HL. Effects of sleep 
and circadian rhythm on human circulating immune cells. J 
Immunol 1997; 158: 4454-64. 
[22]  Uthgenannt D, Schoolmann D, Pietrowsky R, Fehm HL, Born J. 
Effects of sleep on the production of cytokines in humans. 
Psychosom Med1995; 57: 97-104. 
[23]  Irwin M, Mascovich A, Gillin JC, Willoughby R, Pike J, Smith TL. 
Partial sleep deprivation reduces natural killer cell activity in 
humans. Psychosom Med 1994; 56: 493-8. 
[24]  Irwin M, McClintick J, Costlow C, Fortner M, White J, Gillin JC. 
Partial night sleep deprivation reduces natural killer and cellular 
immune responses in humans. FASEB J 1996; 10: 643-53. 
[25]  Irwin M, Thompson J, Miller  C, Gillin JC, Ziegler M. Effect of 
sleep and sleep deprivation on catecholamine and interleukin-2 
levels in humans: Clinical implications. J Clin Endocrinol Metab 
1999; 84: 1979-85. 
[26]  Meier-Ewert HK, Ridker PM, Rifai N, et al. Effect of sleep loss on 
C-reactive protein, an inflammatory marker of cardiovascular risk. 
J Am Coll Cardiol 2004; 43: 678-83.  
[27]  Folkow B. Mental stress and its importance for cardiovascular 
disorders; physiological aspects, “from-mice-to-man”. Scand 
Cardiovasc J 2001; 35: 163-72. 
[28]  Buell P, Breslow L. Mortality from coronary heart disease in 
California men who work long hours. J Chorn Dis 1960; 11: 615-
26. 
[29]  Falger PR, Schouten EGW. Exhaustion, psychological stressors in 
the work environment, and acute myocardial infarction in adult 
men. J Psychosom Res 1992; 36: 777-86. 
[30]  Netterstrom B, Nielsen FE, Kristensen TS, Bach E, Moller L. 
Relation between job strain and myocardial infarction: a case 
control study. Occup Environ Med 1999; 56: 339-42. 
[31]  Theorell T, Rahe RH. Behavior and life satisfactions characteristics 
of Swedish subjects with myocardial infarction. J Chron Dis 1972; 
25: 139-47. 
[32]  Sokejima S, Kagamimori S. Working hours as a risk factor for 
acute myocardial infarction in Japan: case-control study. BMJ 
1998; 317: 775-80. Cardiovascular Disease- a Review of the Recent Literature  Current Cardiology Reviews, 2010, Vol. 6, No. 1    61 
[33]  Partinen M, Putkonen PT, Kaprio J, Koskenvuo M, Hilakivi I. 
Sleep disorders in relation coronary heart disease. Acta Med Scand 
1982; 660(suppl): 69-83. 
[34]  Liu Y, Tanaka H. The Fukuoka Heart Study Group, Overtime 
work, insufficient sleep, and risk of non-fatal acute myocardial 
infarction in Japanese men. Occup Environ Med 2002; 59: 447-51. 
[35]  Ayas NT, White DP, Manson JE, et al. A prospective study of 
sleep duration and coronary heart disease in women. Arch Intern 
Med 2003; 163: 205-9. 
[36]  Spiegel K, Leproult R, Van Cauter E. Impact of sleep dept on 
metabolic and endocrine function. Lancet 1999; 354: 1435-39. 
[37]  Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep 
loss: a novel risk factor for insulin resistance and type 2 diabetes. J 
Appl Physiol 2005; 99: 2008-19. 
[38]  Gottlieb DJ, Punjabi NM, Newman AB, et al. Association of sleep 
time with diabetes mellitus and impaired glucose tolerance. Arch 
Intern Med 2005; 165: 863-7. 
[39]  Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk 
factor for the development of type 2 diabetes. Diabetes Care 2006; 
29: 657-61. 
[40]  Leproult R, Copinschi G, Buxton O, Van Cauter E. Sleep loss 
results in and elevation of cortisol levels the next evening. Sleep 
1997; 20: 865-70. 
[41]  Luboshitzky R, Zabari Z, Shen-Orr Z, Herer P, Lavie P. Disruption 
of the nocturnal testosterone rhythm by sleep fragmentation in 
normal men. J Clin Endocrinol Metab 2001; 86: 1134-9. 
[42]  Barrett-Connor E, Khaw KT. Endogenous sex hormones and 
cardiovascular disease in men: A prospective population based-
study. Circulation 1988; 78: 539-45. 
[43]  Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin 
resistance, body fat distribution, and sex hormones in men. 
Diabetes 1994; 43: 212-9. 
[44]  Simon D, Preziosi P, Barrett-Connor E, et al. Interrelation between 
plasma testosterone and plasma insulin in healthy adult men: the 
Telecom Study. Diabetologia 1992; 35: 173-7. 
[45]  Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. 
Testosterone, sex hormone-binding globulin, and the development 
of type 2 diabetes in middle-aged men: prospective results from the 
Massachusetts Male Aging Study. Diabetes Care 2000; 23: 490-4. 
[46]  Haffner SM, Laakso M, Miettinen H, Mykkanen L, Karhapaa P, 
Rainwater DL. Low levels of sex hormone-binding globulin and 
testosterone are smaller, denser low density lipoprotein in 
normoglycemic men. J Clinic Endocrinol Metab 1996; 81: 3697-
701. 
[47]  Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: 
Sleep curtailment in healthy young men is associated with 
decreased leptin levels, elevated ghrelin levels, and increased 
hunger and appetite. Ann Intern Med 2004; 141: 846-50. 
[48]  Reaven GM, Lithell H, Landsberg L. Hypertenison and associated 
metabolic abnormalities: the role of insulin resistance and the 
sympathoadrenal system. N Engl J Med 1996; 334: 374-81. 
[49]  Larsen PJ, Enquist LW, Card JP. Characterization of the 
multisynaptic neuronal control of the rat pineal gland using viral 
transneuronal tracing. Eur J Neurosci 1998; 10: 128-45. 
[50]  Teclemariam-Mesbah R, Kalsbeek A, Buijs RM, Pevet P. Oxytocin 
innervation of spinal preganglionic neurons projecting to the 
superior cervical ganglion in the rat. Cell Tissue Res1997; 287: 
481-6. 
[51]  Teclemariam-Mesbah R, Ter Horst GJ, Postema F, Wortel J, Bujis 
RM. Anatomical demonstration of the suprachiasmatic nucleus-
pineal pathway. J Comp Neurol 1999; 406: 171-82. 
[52]  Kalsbeek A, Drijfhout WJ, Westerink BH, et al. GABA receptors 
in the region of the dorsomedial hypothalamus of rats are 
implicated in the control of melatonin and corticosterone release. 
Neuroendocrinology 1996; 63: 69-78. 
[53]  Kalsbeek A, Garidou ML, Palm IF, et al. Melatonin sees the light: 
blocking GABA-ergic transmission in the paraventricular nucleus 
induces daytime secretion of melatonin. Eur J Neurosci 2000; 12: 
3146-54. 
[54]  Cui LN, Coderre E, Renaud LP. Glutamate and GABA mediate 
suprachiasmatic nucleus inputs to spinal-projecting paraventricular 
neurons. Am J Physiol Regul Integr Comp Physiol 2001; 281: 
R1283-9. 
[55]  Gerendai I, Toth IE, Boldogkoi Z, Medveczky I, Halasz B. CNS 
structures presumably involved in vagal control of ovarian 
function. J Auton Nerv System 2000; 80: 40-5. 
[56]  La Fleur SE, Kalsbeek A, Wortel J, Buijs RM. Polysynaptic neural 
pathways between the hypothalamus, including the suprachiasmatic 
nucleus, and the liver. Brain Res 2000; 871: 50-6. 
[57]  Buijs RM, Chun SJ, Niijima A, Romijn HJ, Nagai K. 
Parasympathetic and sympathetic control of the pancreas: a role for 
the suprachiasmatic nucleus and other hypothalamic centers that 
are involved in the regulation of food intake. J Comp Neurol 2001; 
431: 405-23. 
[58]  Kreier F, Fliers E, Voshol PJ, et al. Selective parasympathetic 
innervation of subcutaneous and intra-abdominal fat – functional 
implications. J Clin Invest 2002; 110: 1243-50. 
[59]  Nagai K, Nagai N, Shimizu K, Chun S, Nakagawa H, Niijima A. 
SCN output drives the autonomic nervous system: with special 
reference to the autonomic function related to the regulation of 
glucose metabolism. Prog Brain Res 1996; 111: 253-72. 
[60]  Kalsbeek A, Strubbe JH. Circadian control of insulin secretion and 
glucose homeostasis is independent of the temporal distribution of 
feeding. Physiol Behav 1998; 63: 553-8. 
[61]  La Fleur SE, Kalsbeek A, Wortel J, Fekkes ML, Buijs RM. A daily 
rhythm in glucose tolerance: a role for the suprachiasmatic nucleus. 
Diabetes 2001; 50: 1237-43. 
[62]  Pickering TG. The clinical significance of diurnal blood pressure 
variations. Dippers and nondippers. Circulation 1990; 81: 700-2. 
[63]  Yamamoto M, Yamasaki Y, Kodama M, et al. Impaired diurnal 
cardiac autonomic function in subjects with type 2 diabetes. 
Diabetes Care 1999; 22: 2072-7. 
[64]  Goncharuk VD, van Heerikhuize J, Dai JP, Swaab DF, Buijs RM. 
Neuropeptide changes in the suprachiasmatic nucleus in primary 
hypertension indicate functional impairment of the biological 
clock. J Comp Neurol 2001; 431: 320-30. 
[65]  Borghi C, Costa FV, Boschi S, Mussi A, Ambrosioni E. Predictors 
of stable hypertension in young borderline subjects: a five-year 
follow-up study. J Cardiovas Pharmacol 1986; 8(Suppl 5): S138-
41. 
[66]  Eilam R, Malach R, Bergmann F, Segal M. Hypertension induced 
by hypothalamic transplantation from genetically hypertensive to 
normotensive rats. J Neurosci 1991; 11: 401-11. 
[67]  Dunning BE, Ahren B, Veith RC, Taborsky GJ Jr. Noradrenergic 
sympathetic neural influence on basal pancreatic hormone 
secretion. Am J Physiol 1988; 255: E785-92. 
[68]  Scheer FA, Van Montfrans GA, van Someren EJ, Mairuhu G, Buijs 
RM. Daily nighttime melatonin reduces blood pressure in male 
patients with essential hypertension. Hypertension 2004; 43: 192-7. 
[69]  Cagnacci A, Cannoletta M, Renzi A, Baldassari F, Arangino S, 
Volpe A. Prolonged melatonin administration decreases nocturnal 
blood pressure in women. Am J Hypertens 2005; 18: 1614-8. 
[70]  Grossman E, Laudon M, Yalcin R, et al. Melatonin reduces night 
blood pressure in patients with nocturnal hypertension. Am J Med 
2006; 119: 898-902. 
[71]  Simko F, Paulis L. Melatonin as a potential antihypertensive 
treatment. J Pineal Res 2007; 42: 319-22. 
 
 
Received: June 1, 2009  Revised: July 7, 2009             Accepted: July 10, 2009 
 